Springer Nature
Browse
40425_2019_723_MOESM1_ESM.docx (98 kB)

Additional file 1: of Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Download (98 kB)
journal contribution
posted on 2019-10-22, 19:05 authored by Arun Rajan, Christopher Heery, Anish Thomas, Andrew Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi Madan, Leomar Ballester, Stefania Pittaluga, Renee Donahue, Yo-Ting Tsai, Lauren Lepone, Kevin Chin, Fiona Ginty, Anup Sood, Stephen Hewitt, Jeffrey Schlom, Raffit Hassan, James Gulley
Table S1. Flow-cytometry analysis of immune subsets. Subsets analyzed included 9 standard immune subsets (PD-L1 and PD-1 expression analysis was performed for all standard subsets) and 96 subsets relating to maturation and function of immune cells. Table S2. Details of autoimmune adverse events associated with treatment. Table S3. Association of avelumab-related response and irAEs with prior treatment with sunitinib. Table S4. Association between steroid use and response in patients responding to treatment. (DOCX 96 kb)

Funding

National Cancer Institute/National Institutes of Health

History

Usage metrics

    Springer Nature

    Categories

    Keywords

    ThymomaImmunotherapyAvelumabImmune-related adverse eventsImmunosuppressive therapyAnti-PD-L1

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC